Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial

Study limitation reported by the research below: “Non-inferiority to QIVr for A/H3N2 was not achieved; this strain-specific immunogenicity gap may be clinically relevant in seasons where A/H3N2 predominates.”